A Peek Into Bristol-Myers Squibb's Debt

Shares of Bristol-Myers Squibb BMY rose by 0.41% in the past three months. Before having a look at the importance of debt, let us look at how much debt Bristol-Myers Squibb has.

Bristol-Myers Squibb's Debt

According to the Bristol-Myers Squibb’s most recent financial statement as reported on August 6, 2020, total debt is at $46.67 billion, with $41.85 billion in long-term debt and $4.82 billion in current debt. Adjusting for $19.93 billion in cash-equivalents, the company has a net debt of $26.74 billion.

Shareholders look at the debt-ratio to understand how much financial leverage a company has. Bristol-Myers Squibb has $128.08 billion in total assets, therefore making the debt-ratio 0.36. Generally speaking, a debt-ratio more than one means that a large portion of debt is funded by assets. As the debt-ratio increases, so the does the risk of defaulting on loans, if interest rates were to increase. Different industries have different thresholds of tolerance for debt-ratios. A debt ratio of 25% might be higher for one industry and normal for another.

Importance Of Debt

Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.

However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsIntraday UpdateMarketsDebt Insights
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!